BioCentury
ARTICLE | Clinical News

BPS-804 regulatory update

March 2, 2017 10:59 PM UTC

EMA selected for its adaptive pathways program BPS-804 from Mereo to treat osteogenesis imperfecta (OI). The human mAb inhibiting sclerostin has Orphan Drug designation in the U.S. and EU and has completed Phase II testing for the indication. Mereo gained BPS-804 from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in 2015 (see BioCentury, Aug. 3, 2015)...

BCIQ Company Profiles

Novartis AG

BCIQ Target Profiles

Sclerostin